News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Exiqon A/S Announces Achievement of Primary Milestones in RNAi Project for Tacere Therapeutics, Inc.


9/15/2009 8:46:43 AM

VEDBAEK, Denmark, Sept. 15, 2009 (GLOBE NEWSWIRE) -- Exiqon A/S (Copenhagen:EXQ) today announced the successful completion of several key milestones in a custom-designed RNAi project for Tacere Therapeutics. This project resulted from a collaboration between Tacere and Pfizer Inc. to develop and commercialize the TT-033 family of compounds to provide a potential single-administration treatment for the Hepatitis C virus (HCV).

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES